platinum has been researched along with Anorexia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, D; Birnbaum, MJ; Breen, DM; Calle, RA; Collins, S; Esquejo, RM; He, T; Joaquim, S; Joyce, A; Kim, H; Lambert, M; Lin, L; Pettersen, B; Qiao, S; Rossulek, M; Weber, G; Wu, Z; Zhang, BB | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Boku, N; Gotoh, M; Matsumura, Y; Muro, K; Mutoh, M; Nagashima, F; Ohtsu, A; Sano, Y; Shirao, K; Tanigawara, Y; Yamada, Y | 1 |
2 trial(s) available for platinum and Anorexia
| Article | Year |
|---|---|
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Topics: Adult; Anorexia; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Platinum | 2006 |
1 other study(ies) available for platinum and Anorexia
| Article | Year |
|---|---|
GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates.
Topics: Animals; Anorexia; Antineoplastic Agents; Female; Growth Differentiation Factor 15; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, SCID; Neoplasms; Platinum; Vomiting; Weight Loss | 2020 |